The multidrug therapy (MDT) for leprosy consists of mixing antibiotics with other chemicals

The disease is classified into two types: paucibacillary and multibacillary, based on the number of bacteria present. A paucibacillary disease patient has five or fewer poorly pigmented, numb skin patches, whereas a multibacillary disease patient has more than five skin patches. It is estimated that two to three million people worldwide are permanently disabled as a result of leprosy. India has the most cases, with Brazil coming in second and Indonesia coming in third. Multidrug therapy (MDT) is a common leprosy treatment that combines antibiotics. This means you'll be taking two or more medications, most likely antibiotics. You may also be prescribed anti-inflammatory medications to alleviate nerve pain and damage caused by leprosy.

There are several leprostatic agents available for treatment. All people with leprosy should take a 3-drug regimen of rifampicin, dapsone, and clofazimine for 6 months for paucibacillary leprosy and 12 months for multibacillary leprosy. Multidrug therapy (MDT) is still highly effective, and after the first monthly dose, people are no longer infectious. Because it is presented in calendar blister packs, it is safe and simple to use in the field. Relapse rates after treatment remain low. Although the number of cases is small, resistance has been reported in several countries

Although leprosy has been curable since the mid-twentieth century, it can cause permanent physical impairments and damage to a person's nerves, skin, eyes, and limbs if left untreated. Despite the fact that leprosy is not very infectious and has low pathogenicity, the disease still carries a significant stigma and prejudice. Because of this stigma, leprosy can limit a person's ability to participate in social activities and may also have an impact on the lives of their family and friends. Due to the long incubation period of leprosy, delays in diagnosis after disease onset, and a lack of medical care in affected areas, the number of new leprosy cases is difficult to measure and monitor. The disease burden is calculated using the disease's registered prevalence. The number of active leprosy cases diagnosed with the disease and receiving treatment with MDT at a given point in time is reflected in registered prevalence, which is a useful proxy indicator of disease burden.

Read More…